Halozyme Therapeutics HALO
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Halozyme Therapeutics (HALO) Business Model and Operations Summary
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Key Insights
Halozyme Therapeutics (HALO) Core Market Data and Business Metrics
Latest Closing Price
$61.87Market Cap
$7.66 BillionPrice-Earnings Ratio
18.04Total Outstanding Shares
123.53 Million SharesTotal Employees
350Dividend
No dividendIPO Date
March 12, 2004SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
12390 El Camino Real, San Diego, CA, 92130
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $479.06 Million |
| Net Cash Flow From Investing Activities, Continuing | $-262.72 Million |
| Net Cash Flow From Financing Activities | $-218.86 Million |
| Net Cash Flow | $-2.52 Million |
| Net Cash Flow, Continuing | $-2.52 Million |
| Net Cash Flow From Investing Activities | $-262.72 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Available To Common Stockholders, Basic | $444.09 Million |
| Net Income/Loss | $444.09 Million |
| Operating Expenses | $304.43 Million |
| Gross Profit | $855.91 Million |
| Diluted Earnings Per Share | $3.43 |
| Research and Development | $79.05 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $457.20 Million |
| Other Comprehensive Income/Loss | $457.20 Million |
| Comprehensive Income/Loss | $457.20 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Inventory | $141.86 Million |
| Current Assets | $1.09 Billion |
| Other Current Assets | $907.16 Million |
| Noncurrent Liabilities | $1.56 Billion |
| Other Non-current Liabilities | $54.76 Million |
| Prepaid Expenses | $36.32 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||